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Abstract
Background: Hyperglycaemia in diabetes mellitus (DM) alters gene expression regulation in
various organs and contributes to long term vascular and renal complications. We aimed to
generate novel renal genome-wide gene transcription data in rat models of diabetes in order to
test the responsiveness to hyperglycaemia and renal structural changes of positional candidate
genes at selected diabetic nephropathy (DN) susceptibility loci.
Methods: Both Affymetrix and Illumina technologies were used to identify significant quantitative
changes in the abundance of over 15,000 transcripts in kidney of models of spontaneous (genetically
determined) mild hyperglycaemia and insulin resistance (Goto-Kakizaki-GK) and experimentally
induced severe hyperglycaemia (Wistar-Kyoto-WKY rats injected with streptozotocin [STZ]).
Results: Different patterns of transcription regulation in the two rat models of diabetes likely
underlie the roles of genetic variants and hyperglycaemia severity. The impact of prolonged
hyperglycaemia on gene expression changes was more profound in STZ-WKY rats than in GK rats
and involved largely different sets of genes. These included genes already tested in genetic studies
of DN and a large number of protein coding sequences of unknown function which can be
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considered as functional and, when they map to DN loci, positional candidates for DN. Further
expression analysis of rat orthologs of human DN positional candidate genes provided functional
annotations of known and novel genes that are responsive to hyperglycaemia and may contribute
to renal functional and/or structural alterations.
Conclusion: Combining transcriptomics in animal models and comparative genomics provides
important information to improve functional annotations of disease susceptibility loci in humans
and experimental support for testing candidate genes in human genetics.
Background
Diabetes mellitus (DM) is a growing cause of end stage
renal disease in developed countries. Diabetic nephropa-
thy (DN) develops in 35–40% of diabetic patients as the
result of intrarenal metabolic, hemodynamic and struc-
tural changes [1,2]. DN is a complex phenotype caused by
the combined effects of susceptibility alleles and environ-
mental factors which contribute to poor glycaemic control
and hypertension [3]. The importance of genetic factors in
DN is suggested by epidemiological studies and by the
familial clustering of nephropathy in both type 1 and type
2 DM [4-6]. Nephropathy does not necessarily develop in
a significant proportion of diabetic patients, suggesting
the involvement of specific genes.
Genetic studies of nephropathy in diabetic patients are
hampered by heterogeneous clinical features, including
frequent association with hypertension, and between-
study variation in design and phenotype assessment [7].
Although genome-wide linkage studies have identified
regions of the human genome contributing to DN [8-12],
the causative genes remain unknown. Association studies
have been carried out with DN candidate genes that regu-
late blood pressure, the synthesis and degradation of renal
structural components, the metabolism and transport of
glucose and the process of advanced glycation [1,13,14].
High-throughput transcription profiling technologies,
which are powerful tools for determining gene expression
regulation in health and disease situations, can enrich
genome annotations and uncover new DN candidates
[14-16]. Such studies in patients and controls pose techni-
cal, scientific and ethical issues [17].
Animal models of DM are essential components of
genetic and functional genomic investigations. They
include animals made insulin-deficient by injection with
the toxin streptozotocin (STZ) and inbred models of
spontaneous DM [18]. The inbred Goto Kakizaki (GK) rat
shows genetically determined alterations of glucose toler-
ance and insulin secretion [19], and renal structural
changes similar to those observed in the early phase of
DN, including thickening of the glomerular and tubular
basement membranes, and glomerular hypertrophy
[20,21]. Elevation of glomerular macrophage infiltration
is present whereas proteinuria has not been consistently
observed. In contrast STZ-treated animals show little evi-
dence of renal histopathology limited to mild glomerular
mesangial expansion, which is correlated with blood glu-
cose levels and proteinuria [22,23]. The genetic basis of
these renal phenotypes in these diabetic models has not
been investigated. These models underlie clearly different
etiological and pathological contexts of DM, and provide
complementary tools to document hyperglycaemia-
induced gene expression changes that can contribute to
the development of renal structural and functional anom-
alies relevant to DN.
In this study, we have investigated the effects of prolonged
hyperglycaemia on genome-wide renal gene expression
regulation in GK rats and inbred rats of similar genetic ori-
gin (Wistar-Kyoto, WKY) made severely diabetic by STZ,
which may be caused by differential adaptations to mild
or severe hyperglycaemia induced by genetic variants in
GK and environmental changes in both diabetic models.
We specifically demonstrated the possibility to use data
from both comparative genomics and gene transcription
regulation to test transcriptional responsiveness of genes
to hyperglycaemia and renal structural changes that can
improve functional annotations of known and potentially
novel positional candidate genes localised in DN suscep-
tibility loci.
Methods
Animals
Rats of the GK strain from the Oxford colony (GK/Ox)
were used. WKY control rats were purchased from a com-
mercial supplier (Harlan, UK). All animal procedures
complied with the University of Oxford's Local Ethical
Review Process and were carried out under project licences
30/2001 and 30/2324 granted by the UK Home Office. A
group of 3 month old WKY rats was injected intravenously
with a solution of Streptozotocin (STZ) (Sigma-Aldrich,
Poole, UK) at 75 mg/kg in citrate buffer (pH 4.5) to
induce permanent and severe insulin deficiency and
hyperglycaemia of about 16.6 mM. This group is referred
as STZ-WKY. Experiments were performed with male rats
fed standard laboratory chow pellets (B&K Universal,
Hull, UK) and kept on 12 h light/dark cycle. Body weight
and plasma glucose were monitored. GK and WKY rats
were killed at 3 months by CO2 asphyxiation, whereasBMC Medical Genomics 2009, 2:41 http://www.biomedcentral.com/1755-8794/2/41
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STZ-WKY rats were killed at 6 months to ensure that dura-
tion of hyperglycaemia in both diabetic models was simi-
lar (ie. 3 months). WKY rats were used as pre STZ-treated
controls for the STZ-WKY group. The left kidney was
removed, snap-frozen in liquid nitrogen and stored at -
80°C until RNA preparation. The right kidney was fixed in
Dubosq-Brazil (0.4% picric acid, 27% formalin, 7% acetic
acid, 54% ethanol) and embedded in paraffin. Sections (3
μm) were stained with periodic acid-Schiff (PAS) reagent
and counterstained with hematoxylin (Sigma-Aldrich,
Poole, UK). Presence of renal anomalies in diabetic rats
was evaluated by examining 3 sections per rat.
RNA preparation
Total kidney RNA samples were individually prepared
from four (GK, WKY) or five (STZ-WKY) animals per
group. Total RNA was extracted twice using Trizol reagents
(Invitrogen Life Technologies, Paisley, UK) and cleaned
with RNeasy columns (Qiagen Ltd., Crawley, UK). RNA
quality was determined with an Agilent 2100 Bioanalyzer
(Agilent Technologies, Waldbronn, Germany).
Hybridization to Affymetrix gene expression arrays
Synthesis of cDNA and biotin-labeled cRNA (Affymetrix
ltd., High Wycombe, UK) was performed using 14 μg of
RNA. Biotinylated cRNA (15 μg) were fragmented and
individually hybridized to GeneChip Rat expression
Arrays 230A containing 15,866 probe sets (Affymetrix
ltd., High Wycombe, UK). Best quality samples from three
animals per group were used and individually hybridized
to the arrays. Washing and staining procedures were per-
formed using a Fluidics Station 450 according to manu-
facturer's protocol (Affymetrix ltd, High Wycombe, UK).
Arrays were scanned at 560 nm using an array scanner
(Agilent Technologies, Waldbronn, Germany).
Hybridization to Illumina gene expression arrays
Replication experiments were carried out with Illumina
arrays, a bead-based technology that is different from that
of Affymetrix. Double-stranded cDNA and biotin-labelled
cRNA were synthesized from RNA (300 ng) using the Illu-
mina® TotalPrep RNA amplification it (Ambion Inc., Aus-
tin, TX). Each biotinylated cRNA (750 ng) was hybridized
to prototype Sentrix®  BeadChip RatRef-12_V1_Eval
Whole-Genome Gene Expression arrays containing
22,636 oligonucleotides (Illumina Inc., San Diego, CA).
For each rat group, individual hybridizations were per-
formed in technical duplicates with 4 biological repli-
cates, including the three samples previously used for the
Affymetrix experiments. Following washing steps and
staining with Streptavidin-Cy3, arrays were scanned on
the Illumina® BeadArray Reader and the images analyzed
using the Illumina BeadStudio software.
Experiments are MIAME compliant. Protocols and data
are available through ArrayExpress http://www.ebi.ac.uk/
arrayexpress/ under the accession E-MEXP-1195 (Affyme-
trix) and E-TABM-502 (Illumina).
Quantitative real time PCR
First-strand cDNA were synthesized from total RNA with
Superscript II cDNA synthesis kits (Invitrogen Gibco, Pais-
ley, UK). QRT-PCR was performed with oligonucleotides
designed to span an intron/exon boundary (see Addi-
tional file 1) using a Rotor-Gene 3000™ system (Corbett
Research, Milton, UK) and QuantiTect SYBR Green PCR
kits (Qiagen Ltd, Crawley, UK). Experiments were per-
formed with biological quadruplicates (ie. the four sam-
ples used for the Illumina experiments) and technical
triplicates. Analyses were performed using the Rotor-Gene
software (Corbett Research, Milton, UK). Gene dosage
was calculated with the standard curve generated and nor-
malized to actin.
Gene transcription data analysis
The renal Affymetrix and Illumina gene expression data-
sets were previously used alongwith other rat and mouse
datasets to test and optimise appropriate methods for
analysis, including data extraction and normalisation pro-
cedures [24]. Analysis of Affymetrix CEL file data was per-
formed using the Bioconductor packages in the R
language and environment as previously described [25].
Briefly, Affymetrix data were normalized using the RMA
method and the linear model for microarray data
(LIMMA) package was used to assess significance between
groups. For Illumina, microarray results were normalized
by quantile normalization and LIMMA was used to calcu-
late significant differences between groups using slide
number as a covariate to correct for chip-specific effects.
Affymetrix and Illumina datasets were used independ-
ently to carry out statistical data analyses of gene expres-
sion changes between rat groups. Cross-platform
consistency of statistical significance and fold change of
renal gene expression have been reported elsewhere [24].
For both Affymetrix and Illumina datasets, P-values were
corrected for multiple testing using a 5% false discovery
rate as the cut-off for significance. Data from QRT-PCR-
based gene transcription analysis were analysed using
SPSS version 16.0 statistical package. A Bonferroni post
hoc test was used to assess differences between the dia-
betic models and the normoglycemic WKY strain as well
as between the two diabetic models. A p value of less than
0.05 was considered to be statistically significant for pair-
wise comparisons.
Results
Pathophysiological features in GK and STZ-WKY rats
The effect of prolonged diabetes on gene expression
changes was determined in situations of similar durations
(3 months) of mild spontaneous (GK) or severe experi-
mentally-induced (STZ-WKY) hyperglycaemia. Glycaemia
in STZ-WKY rats was monitored to be greater than 13.5BMC Medical Genomics 2009, 2:41 http://www.biomedcentral.com/1755-8794/2/41
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mM and not to exceed 16.6 mM throughout of the 3
months of the experiment. Glycaemia was significantly
more elevated in GK and STZ-WKY rats than in WKY con-
trols (Additional file 2). Body weight was similar in GK
and WKY rats. Prolonged severe hyperglycaemia in 6
months old STZ-WKY rats resulted in marked decreased
body weight when compared to 3 months old WKY con-
trols
The two diabetic models showed mild renal histopatho-
logical changes, which may be relevant to early patholog-
ical events in DN progression. When compared to age-
matched WKY (Additional file 3A), GK rats showed
glomerular alterations including basement membrane
thickening, matrix accumulation of hyaline, indicating
mesangial extracellular matrix expansion, and increased
capillary luminal volume suggesting glomerular hypertro-
phy (Additional files 3B3 and 3C). Tubular basement
membrane thickening was observed in both collecting
and distal tubules of GK sections. Following three months
of severe hyperglycaemia, STZ-WKY rats exhibited glomer-
ular hypertrophy associated with capillary loop expansion
and to a lesser extend basement membrane thickening
and mild mesangial expansion (Additional files 3D–F).
Affymetrix-based genome-wide renal transcription profiles 
in diabetic rats
Overview of gene transcription changes
Pairwise comparisons of microarray data between rat
groups sharing similar genetic backgrounds of Wistar ori-
gin were performed to provide detailed information on
transcriptional responses to prolonged and permanent
hyperglycaemia (GK or STZ-WKY compared to WKY), as
well as specific changes caused by gene variants predispos-
ing to diabetes and possibly kidney histopathology (GK
compared to WKY) and underlying hyperglycaemia sever-
ity (GK compared to STZ-WKY). Of the probe sets repre-
senting known and predicted transcripts, 252 were found
differentially regulated between GK and WKY rats and
over 650 between STZ-WKY and WKY, indicating a greater
impact of severe hyperglycaemia on renal transcriptional
changes (Figure 1). Over 800 genes were differentially
expressed between STZ-WKY and GK suggesting that renal
transcriptome adaptations to hyperglycaemia in these
models involve different mechanisms. Furthermore,
when compared to WKY, diabetic models shared tran-
scriptional changes for only 74 genes (corresponding to
80 probesets), which generally showed the same pattern
of expression regulation (Figure 2 and additional file 4).
In all comparisons there were similar numbers of genes
up- and down-regulated. There was no evidence of
genomic clustering of differentially expressed genes (data
not shown). Pathway analysis identified gene expression
mechanisms either consistently affected in both diabetic
models or predominantly altered in the GK or STZ-WKY
rats (Additional file 5).
Transcription regulation of functional candidate genes in diabetic 
models
To gain insight into DN candidates, expression regulation
of individual genes was analyzed. Evidence of significant
differential expression in at least one of the comparisons
between the three models was found for 1,233 Affymetrix
probe sets representing 713 known genes and 468
expressed sequence tags (ESTs) and predicted genes (see
Additional file 4). Owing to their relevance to mecha-
nisms involved in DN [26], a number of these genes have
already been tested for evidence of genetic association to
DN [13,27,28], including genes encoding the angiotensin
converting enzyme (Ace), angiotensinogen (Agt), ang-
iogenin ribonuclease A family 5 (Ang), apolipoprotein E
(Apoe), bone morphogenetic protein 7 (Bmp7), carnosi-
nase 1 (Cndp1), collagens type IV (Col4a1, Col4a4), con-
nective tissue growth factor (Ctgf), cathepsin L (Ctsl),
epidermal growth factor (Egf), gremlin 1 (Grem1),
integrin, alpha 1 (Itga1), laminin beta 1 (Lamb1), lectin
galactoside-binding soluble 3 (Lgals3), lipoprotein lipase
(Lpl), matrix metalloproteinase 9 (Mmp9), nidogen (Nid),
nitric oxide synthase (Nos), neuropilin 1 (Nrp1), renin
(Ren), SA hypertension-associated homolog (Sah), glu-
cose transporter 2 (Slc2a2), a sodium/chloride transporter
(Slc12a3), hepatic transcription factor 2 (Tcf2, Hnf1b1),
Differentially expressed genes in kidneys of GK and STZ- induced diabetic rat models Figure 1
Differentially expressed genes in kidneys of GK and 
STZ-induced diabetic rat models. Number of Affymetrix 
probesets corresponding to genes statistically differentially 
expressed between models (p < 0.05) are shown. The full list 
of differentially expressed genes between the three models is 
given in Additional file 4.BMC Medical Genomics 2009, 2:41 http://www.biomedcentral.com/1755-8794/2/41
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transcobalamin 2 (Tcn2), transforming growth factor beta
1-induced transcript 4 (Tgfb1i4) and transmembrane 4
superfamily member 4 (Tm4sf4). Related genes and other
candidates previously tested in DN genetics [13] were
found differentially expressed between models, including
genes encoding cathepsins (Ctsb, Ctsf), carboxypeptidases
(Cpe,  Cpn1), methylenetetrahydrofolate dehydrogenase
(Mthfd1) and syndecan 1 (Sdc1), which were consistently
upregulated in STZ-WKY when compared to WKY, and
genes for carnosinase 2 (Cndp2), ectonucleotide phos-
phodiesterase 5 (Enpp5), laminin alpha (Lama1), beta-
galactoside binding lectins (Lgals1,  Lgals2,  Lgals5,
Lgals3bp), matrix metalloproteinases (Mmp11,  Mmp14)
and a matrix-associated regulator of chromatin (Smarca4).
Altered transcription regulation between models was also
found for genes involved in extracellular matrix turnover
(Cdh1, Cdh16, Cdh17, Celsr2, Cyr61, Dag1, Mucdhl, Omd,
Sparc, Spon1) and biochemical processes including the
polyol pathway (Akr1b4, Akr1b8, Akr1c12, Akr7a3, Sord)
and gluthatione metabolim (Gss,  Gstm1,  Gsto1,  Gstp1,
Gstt2, Hagh, Yc2) (Additional file 4) which are relevant to
DN. However, nearly 40% of genes differentially
expressed between diabetic rats correspond to ESTs and
predicted genes, which lack unambiguous annotation but
represent attractive DN candidates, in particular when
they map to rat chromosomal regions conserved with DN
susceptibility loci.
Patterns of transcription for genes consistently differentially expressed between diabetic rats (GK and STZ-WKY) and WKY  controls Figure 2
Patterns of transcription for genes consistently differentially expressed between diabetic rats (GK and STZ-
WKY) and WKY controls. Genes are listed along the X axis with both Affymetrix probe set names and either symbols for 
known genes or accession number references for EST sequences. Genes are ranked from the highest (left) to the lowest (right) 
changes in transcription ratio in the GK vs WKY comparison.BMC Medical Genomics 2009, 2:41 http://www.biomedcentral.com/1755-8794/2/41
Page 6 of 12
(page number not for citation purposes)
Replication of gene expression changes using Illumina 
BeadChips
To evaluate the robustness of transcription changes
detected with Affymetrix arrays, gene expression profiling
was repeated with the same samples using a different tech-
nology (Illumina BeadChips). Technical aspects of
Affymetrix and Illumina array data processing (signal
extraction and normalisation) and cross platforms con-
sistency of results in terms of fold-change of expression
and statistical significance, have been previously
addressed [24]. Of the 1,182 transcripts found differen-
tially regulated in at least one of the comparisons (714
known genes and 468 ESTs), over 750 could be unambig-
uously identified on the Illumina array, including 80% of
known genes (566 genes) and 41% of ESTs (193 ESTs)
(Additional file 6). In all comparisons, replication of
Affymetrix results with Illumina in terms of both statisti-
cal significance of differential expression and direction of
transcriptional change was remarkably high for known
genes, ranging from 83% to 90%, whereas replication rate
for ESTs was more modest (56% to 70%). Lower replica-
tion rate of Affymetrix results by Illumina for ESTs than
known genes may reflect ambiguous annotations of ESTs.
In exceptional cases (Dpt, Hmox2, Pde4d, Slc12a3, Stat3,
Wdfy1 and 7 ESTs) the directions of expression changes
given by Illumina and Affymetrix were inconsistent. Large
numbers of genes were found differentially expressed with
Illumina but not Affymetrix despite very similar expres-
sion ratio. This can be explained by the use of technical
replicates for the Illumina experiments rather than techni-
cal features of the platforms.
Identification of DN functional and positional candidates
To study more specifically expression of genes localized in
DN susceptibility loci, we initially used comparative
genome mapping data [29] to determine that regions of
rat chromosomes 2q24-25, 2q31-32, 3q36-43, 8q12-13,
8q31-32, 11q22-23, 13p12-13, 18p12-13 and 18q12-13
show evidence of synteny conservation with DN loci in
human 3q23-q29, 7q32.3-q33, 18q22-q23 and 20p12.3-
p13. Using EnsEmbl genome annotation and the EnsMart
browser http://www.ensembl.org/, we selected positional
candidate genes and predicted protein coding sequences
at these loci to investigate their expression regulation in
the Affymetrix datasests. There are over 330 annotated
genes and ESTs at these loci, of which over 210 (65%) are
represented on the Affymetrix array. A total of 34 DN posi-
tional candidates were differentially expressed in at least
one of the comparisons between diabetic rats and controls
(Table 1)(Additional file 7). These include candidates
already tested in DN genetic studies (Cndp1, Slc2a2) and
genes known to be exclusively or abundantly expressed in
kidney, such as genes encoding enzymes of the polyol
pathway (Akr1b4, Akr1b8), a kidney specific urea trans-
porter (Slc14a2), a component of renal tight junctions
(Cldn16), a zinc metalloendopeptidase (Mep1b) and a
marker of tubular injury (Rbp1). Altered transcription of
other genes at the loci underlines their possible role in DN
etiology and pathogenesis (Table 1).
To provide information on renal expression of DN posi-
tional candidates not represented on the Affymetrix array,
53 genes localized in the most significant region of DN
loci were selected for quantitative real time PCR (QRT-
PCR) on kidney samples of diabetic and control rats. Rat
orthologs of 23 of these could not be identified using Ens-
Mart. Three genes (AGBL3, CHCHD3, LRGUK) and two
ESTs (Q68DL7, Q6ZU70) are unlikely to be expressed in
kidney as the oligonucleotides for the rat orthologs failed
to amplify renal cDNA. Of the remaining 25 genes, 16
showed evidence of differential expression between dia-
betic and control rats (Table 2). With the exception of an
aldo-keto reductase (Akr1b10), the function of these genes
is largely unknown and their involvement in pathological
mechanisms described in DN has not been reported.
Overall, results from transcriptional analysis of DN posi-
tional candidates in the kidney of diabetic rats provided
novel functional annotations (ie. transcriptional adapta-
tions to hyperglycaemia and renal structural changes) of
known and predicted genes.
Validation of microarray data by QRT-PCR
To further validate transcription changes derived by
microarray platforms, QRT-PCR was carried out with 12
genes selected for their functional relevance to DN (Bmp3,
Bmp6, Grem1, Ctgf, Slc2a2) or Type 2 DM (Arntl, Slc2a2),
their location in DN susceptibility loci (Cldn16, Hrg, Pld1,
Rbp1,  Slc2a2) or the magnitude of the transcriptional
change (JunD, Slc2a2, Tff3) (Figure 3). Results generally
confirm microarray data including the direction of expres-
sion changes. Downregulation of Bmp3 expression in GK
and upregulation of Grem1 in STZ-WKY confirm Illumina
results.
Discussion
We report renal genome-wide gene expression changes
induced by prolonged hyperglycaemia in models of exper-
imentally-induced (STZ-WKY) or spontaneous (GK) dia-
betes, widely used in diabetes research and known to
develop renal alterations [18,20,30]. Two well-established
transcription profiling technologies (Affymetrix and Illu-
mina) provided highly concordant information on the
effects of severe (STZ-WKY) or moderate (GK) hypergly-
caemia, as well as GK-specific diabetes susceptibility
genes, on the expression of over 15,000 known and pre-
dicted genes. Differentially expressed genes, which reflect
mechanisms responsive to hyperglycaemia, provide
improvements in functional annotations of known
and predicted genes and potentially novel targets in DN
genetics.BMC Medical Genomics 2009, 2:41 http://www.biomedcentral.com/1755-8794/2/41
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Renal histological changes in GK and STZ-WKY rats are
relatively mild in these models [21,30-32], which may
therefore be useful for investigating early molecular adap-
tations to hyperglycaemia in DN progression. Genome-
wide gene expression profiling, which allows unbiased
analysis of thousands of genes regardless of their function
and chromosomal position, is a practical approach to
comprehensively assess perturbed mechanisms in GK and
STZ-WKY rats maintained in strictly identical conditions
and uncover renal molecular adaptations to impaired glu-
cose homeostasis in a context where environmental influ-
ences and genetic polymorphisms are minimized, as
inbred WKY and GK strains share extensive genetic simi-
larities outside GK-specific diabetes variants [19,32].
Gene expression results from two well-established and
robust microarray technologies designed to investigate
the transcription of largely overlapping series of genes
[24], which provide systems for assessing data replication,
showed remarkable concordance in transcription regula-
tion patterns. Some discordant results may be explained
by the design of the probesets (Affymetrix) or the oligonu-
cleotides (Illumina) in different gene isoforms or the
Table 1: Genes differentially expressed between diabetic models and controls that map to regions conserved with human DN 
susceptibility loci.
GK vs WKY STZ vs WKY STZ vs GK
Gene Symbol Gene description Genbank TR p-value TR p-value TR p-value
Human 3q23-q29
Bdh 3-hydroxybutyrate dehydrogenase NM_053995 +1.3 Ns -1.2 Ns -1.6 0.007
Centb2 Centaurin beta 2 BM389190 -1.4 Ns 1.0 Ns +1.3 0.047
Clcn2 Chloride channel 2 NM_017137 +1.2 Ns -1.1 Ns -1.4 0.038
Cldn16 Claudin 16 NM_131905 -1.1 Ns -1.6 0.002 -1.4 0.01
Dgkg Diacylglycerol kinase gamma NM_013126 +1.2 Ns +1.6 0.025 +1.3 Ns
Dnajb11 DnaJ (Hsp40) subfamily B11 BI295873 1.0 Ns -1.3 0.043 -1.3 Ns
Eif4g1 Eukaryotic translation initiation factor BC098868 +1.1 Ns -1.2 Ns -1.4 0.011
Fad104 FAD104 (predicted) AI176320 +1.3 Ns -1.3 0.05 -1.7 5 × 10-4
Fam43a Family with sequence similarity 43A BE108405 -1.1 Ns -1.7 0.017 -1.5 Ns
Hrg Histidine-rich glycoprotein NM_133428 -1.2 Ns +2.0 0.034 +2.5 0.007
Mfn1 Mitofusin 1 AI169627 1.0 Ns +1.7 0.046 +1.7 0.035
AA943135 1.0 Ns +1.5 0.018 +1.5 0.009
Ncbp2 Nuclear cap binding protein subunit 2 BI282103 +1.3 Ns -1.5 0.046 -2 0.002
Pld1 Phospholipase D1 U69550 -1.3 Ns -1.8 0.036 -1.4 Ns
Pigx Subunit of GPI-mannosyltransferase AI172192 +1.3 Ns 1.0 Ns -1.3 0.043
Rbp1 Retinol binding protein 1 NM_012733 1.0 Ns +2.3 3 × 10-4 +2.2 3 × 10-4
Siat1 Sialyltransferase 1 M83143 1.0 Ns -1.6 0.002 -1.6 0.001
Slc2a2 Solute carrier family 2 member 2 (Glut2) NM_012879 +3.0 5 × 10-4 +3.6 1 × 10-4 +1.2 Ns
Ssr3 Signal sequence receptor gamma NM_031120 -1.2 Ns +1.3 Ns +1.6 0.003
Zbed4 Zinc finger, BED domain containing 4 AI170289 -1.1 Ns -1.3 0.046 -1.2 Ns
--- Similar to protein NP_079596 AI412011 +1.4 Ns -1.5 0.044 -2.1 0.001
Human 7q32.3-q33
Akr1b4 Aldo-keto reductase family 1B4 NM_012498 1.0 Ns +2.2 Ns +2.1 0.024
Akr1b8 Aldo-keto reductase family 1B8 NM_173136 -6.2 6 × 10-5 +1.4 Ns +8.5 8 × 10-6
Slc35b4 Solute carrier family 35 member B4 XM_216122 +1.2 Ns -1.1 Ns -1.4 0.010
Human 18q12-q23
Acaa2 Acetyl-Coenzyme A acyltransferase 2 NM_130433 -1.6 0.041 -1.3 Ns +1.2 Ns
Brunol4 RNA binding protein bruno-like 4 AW530502 +1.1 Ns +1.3 0.036 +1.2 Ns
Cndp1 Carnosinase 1 AI231438 1.0 Ns -3.4 3 × 10-5 -3.5 8 × 10-6
Cndp2 Carnosinase 2 BI279729 +1.1 Ns -1.3 0.042 -1.4 0.01
G0S2 Putative lymphocyte G0/G1 switch gene AI406939 +1.3 Ns -1.6 Ns -2.1 0.004
Mapk4 Mitogen-activated protein kinase 4 BG378232 +1.3 Ns +1.5 0.023 +1.2 Ns
Mep1b meprin 1 beta (endopeptidase-2) NM_013183 1.0 Ns -1.4 0.042 -1.4 0.050
Pqlc1 PQ loop repeat containing 1 AI228284 +1.6 0.044 +1.7 0.011 +1.1 Ns
Slc14a2 Solute carrier family 14, member 2 NM_019347 -1.1 Ns +1.5 0.020 +1.7 0.005
AF042167 -1.1 Ns +1.4 Ns +1.6 0.035
Human 20p12.3-p13
Cdc25b Cell division cycle 25 homolog B NM_133572 +1.2 Ns +1.6 0.028 +1.4 Ns
Prnp Prion protein NM_012631 +1.6 0.029 +1.1 Ns -1.5 0.030
Gene expression results from Affymetrix chip hybridizations are given as transcription ratio (TR). The list of genes in these regions represented on 
the Affymetrix chip and not differentially expressed is given in Additional file 7. Ns, not statistically significant differences.BMC Medical Genomics 2009, 2:41 http://www.biomedcentral.com/1755-8794/2/41
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existence of polymorphisms in the sequences arrayed on
the chips [33].
Transcriptomic alterations were more profound in STZ-
WKY than in GK and involved largely non-overlapping
sets of genes, thus underlining the importance of investi-
gating gene expression in very different, but complemen-
tary, contexts of diabetes aetiology and pathogenesis. Age
may have a confounding impact on these processes as, for
obvious reasons, the models used were not age-matched,
but the duration of spontaneous (GK) or experimentally-
induced (STZ-WKY) hyperglycaemia was identical (3
months). Along the same line, gene expression differences
between STZ-WKY and WKY, which compare pre- and
post-drug treated groups and test molecular responses to
prolonged and severe hyperglycaemia, may also reflect to
Table 2: Expression regulation of rat orthologs of human genes localised in DN susceptibility loci and not represented on the 
Affymetrix arrays.
GK vs WKY STZ-WKY vs WKY STZ-WKY v GK
Human Ensembl Description Symbol Rat Ensembl TR p-value TR p-value TR p-value
(ENSG00000) (ENSRNO G000000)
Human 3q23
175066 Glycerol kinase 5 GK5 10942 1.00 Ns 0.66 0.026 0.67 2 × 10-3
114120 Solute carrier family 25, 
member 36
SLC25A36 39085 1.28 Ns 1.54 4 × 10-3 1.21 Ns
175093 SPRY domain-containing 
SOCS box protein 4
SPSB4 12862 0.78 Ns 0.37 5 × 10-3 0.47 0.013
114126 Transcription factor Dp-2 
(E2F dimerization partner 2)
TFDP2 11241 0.76 Ns 1.56 Ns 2.04 Ns
114127 5'-3' exoribonuclease 1 XRN1 10027 0.71 Ns 0.66 0.030 0.93 Ns
177311 Zinc finger and BTB domain-
containing protein 38
ZBTB38 12386 1.08 Ns 1.27 0.026 1.17 Ns
206250 Protein coding sequence - 22555 0.81 Ns 0.82 Ns 1.01 Ns
Human 7q33
146856 ATP/GTP binding 
protein-like 3
AGBL3 10397 0.95 Ns 0.52 1 × 10-4 0.55 3 × 10-4
198074 Aldo-keto reductase 1 
member B10
AKR1B10 27433 1.94 0.035 0.77 Ns 0.40 1 × 10-4
122783 Uncharacterized protein 
C7orf49
C7orf49 26958 0.95 Ns 0.59 0.016 0.62 5 × 10-3
Human 18q22.3-23
179981 Teashirt zinc finger homeobox 
1
TSHZ1 16246 0.91 Ns 1.00 Ns 1.10 Ns
141665 F-box only protein 15 FBXO15 38225 0.72 Ns 0.69 Ns 0.97 Ns
130856 Zinc finger protein 236 ZNF236 16303 1.45 0.025 1.48 0.011 1.02 Ns
166540 zinc finger protein 407 ZNF407 16008 0.87 Ns 0.77 0.015 0.88 Ns
101493 Zinc finger protein 516 ZNF516 16258 1.07 Ns 1.20 Ns 1.12 Ns
Human 20p12.3-13
149451 Disintegrin and 
metalloproteinase 33
ADAM33 21242 0.85 Ns 1.28 Ns 1.51 Ns
101222 Uncharacterized protein 
C20orf28
C20orf28 21247 1.19 Ns 0.80 Ns 0.67 0.016
101311 Unc-112-related protein 1 
(Kindlin-1)
C20orf42 21274 0.70 0.050 0.53 2.2 × 10-3 0.75 Ns
125872 Uncharacterized protein 
C20orf75
C20orf75 32989 1.65 Ns 5.48 1 × 10-3 3.31 1 × 10-3
171984 Uncharacterized protein 
C20orf196
C20orf196 21268 1.40 Ns 1.22 Ns 0.87 Ns
125885 Minichromosome maintenance 
complex component 8
MCM8 21272 2.63 Ns 2.82 Ns 1.08 Ns
171864 Prion protein 2 PRND 21260 0.64 Ns 0.53 Ns 0.83 Ns
101236 RING finger protein 24 RNF24 21250 0.81 Ns 0.60 0.010 0.74 Ns
088827 Sialic acid-binding Ig-like 
lectin 1
SIGLEC1 21243 0.73 0.033 0.81 Ns 1.11 Ns
149345 Putative ubiquitin-conjugating 
enzyme E2 D3-like
U2D3L 13741 1.27 Ns 0.64 0.020 0.51 2 × 10-3
The EnsMart browser http://http:www.ensembl.org/ was used to identify human-rat homologies (synteny conservation) in regions of the human 
genome associated with DN. Transcription ratios (TR) between models were assessed by QRT-PCR with kidney samples of GK, STZ-WKY and 
WKY rats previously used to hybridize microarrays. Ns, not statistically significant.BMC Medical Genomics 2009, 2:41 http://www.biomedcentral.com/1755-8794/2/41
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some extent "normal" biological adaptations to ageing
described in WKY [34]. Similar model-specific patterns of
gene expression regulation was observed in renal tran-
scriptomes of mouse models of STZ-induced and sponta-
neous (db/db) diabetes [31]. Diabetes-predisposing
variants in the GK and db/db strains may therefore affect
renal changes through specific mechanisms not necessar-
ily related to hyperglycaemia itself. The existence of such
specific polymorphisms [35] and a genetic predisposition
to salt-induced hypertension [36] are documented in the
GK strain. Metabolic and hormonal factors, as well as
renal structural alterations secondary to impaired glucose
regulation, may also explain the extent of renal transcrip-
tomic differences between STZ-WKY and GK. Insulin defi-
ciency is the leading cause of hyperglycaemia in STZ-
treated animals [37], whereas the GK strain develops insu-
lin resistance, which is associated with DN [38] and may
play a specific role on renal gene expression in GK rats.
Combining transcriptomic results in GK and STZ-WKY
rats with published data in animal models of diabetes
[31,39,40]. and in humans [41,42] contribute to the
enrichment of renal functional pathways that may be
involved in DN. Of note, upregulation of Grem1, a bone
morphogenetic protein antagonist, and strong downregu-
lation of cadherins, Egf and Tff3, a protein promoting epi-
thelial cell restitution, may contribute to renal damage in
STZ-WKY, [43,44]. In GK rats, altered transcription of pro-
liferation and differentiation factors (Bmp3, Bmp6, Bmp7)
[45] suggests the involvement of mechanisms protecting
the kidney against interstitial fibrosis [20], that upregula-
tion of transcripts increasing extracellular matrix produc-
tion (Ctgf, Mmp9) may initiate [46]. Downregulation of
aldo-keto reductases (Akr1b8, Akr1c12, Akr7a3) and
upregulation of Sord (in STZ-WKY) may reflect the activa-
tion of compensatory mechanisms preventing the accu-
mulation of sorbitol and reducing polyol pathway flux
[26]. Stimulated expression of glutathione synthase in GK
may reflect cytoprotective mechanisms, whereas its down-
regulation in STZ-WKY may be balanced by increased
expression of glutathione transferases, therefore contrib-
uting to protect the cells against oxidative stress [47].
However, expression of genes encoding protein known to
play a role in DN pathogenesis, including TGFB, heme
oxygenase (HMOX1), osteopontin (SPP1), were not sig-
nificantly altered in diabetic rats, despite a 30–40% upreg-
ulation.
The primary aim of the study was to identify genes that are
differentially expressed in diabetic models and map to
regions of the rat genome that show evidence of synteny
conservation with human loci associated with DN. As
largely overlapping series of genes are represented on Illu-
mina and Affymetrix arrays, replicated gene transcription
differences with the two technologies provide robust
information for selecting positional and functional DN
candidate genes. Candidates include genes and ESTs that
have no apparent functional relevance to DN, but their
renal transcription patterns indicate a possible role in kid-
ney structural and metabolic alterations. Of note, hepatic
transcription profiling data in the same animals show that
only a small proportion (6%–11%) of genes are consist-
ently differentially expressed in kidney and liver (data not
shown). Comparative genomic analysis of DN positional
Validation of microarray results by quantitative real time PCR Figure 3
Validation of microarray results by quantitative real time PCR. The expression of 12 selected genes was assessed by 
QRT-PCR in kidney samples of GK, STZ-WKY and WKY rats previously used for microarray-based transcription profiling. 
Results are expressed as means ± SE, in percentage of normalized WKY values. *P < 0.05, **P < 0.01 statistically significantly 
different to WKY controls.BMC Medical Genomics 2009, 2:41 http://www.biomedcentral.com/1755-8794/2/41
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candidates mapped to 3q, 7q, 18q and 20p [8-11]
revealed several differentially expressed genes that have
not been tested in genetic studies of DN [13,27,28] and
may therefore be important in genetic and clinical inves-
tigations of DN. Among relevant genes, Slc14a2 encodes a
vasopressin-dependent urea transporter expressed in the
collecting duct. Its upregulation in STZ-WKY may contrib-
ute to nitrogen conservation in response to glucosurea
[48]. In these rats, downregulation of Cldn16, a major
structural component of tight junction in the ascending
limb of Henle, may result in ions wasting and renal
glomerular and tubular alterations [49,50]. Finally,
altered renal transcription of Rbp1 and Mep1b has been
reported in mouse models of experimentally-induced dia-
betes [31] and tubular fibrosis [51].
Positional candidates differentially expressed in diabetic
rats also include protein coding sequences predicted by
bioinformatic models which nevertheless represent
important functional DN candidates. Even though
genome annotations and microarray technologies keep
improving, potentially important DN positional candi-
date genes are not represented on gene expression arrays.
Systematic renal expression analysis of ESTs mapped to
the most significant regions of DN loci identified tran-
scripts differentially regulated between GK and STZ-WKY
rats. Of note, using quantitative RT-PCR, we found evi-
dence of significant changes in expression for transcripts
predicted to encode a further aldo-keto reductase
(Akr1b10) and the zinc finger protein 236, which has been
tested as a DN candidate [52]. In the vast majority of
cases, confirmation of gene organization and biological
functions, including altered protein abundance, is
required. Although we prioritized our study to gene
expression studies in total kidney to take into account
interactions between renal cell types in the regulation of
organ function, further investigations in tubular and
mesangial cells will establish tissue specific gene expres-
sion patterns.
Conclusion
Our study illustrates a pertinent approach utilizing both
functional and positional criteria for selecting disease can-
didate genes. It provides a comprehensive survey of differ-
ential renal transcription adaptations to prolonged severe
or moderate hyperglycaemia which likely involve patho-
physiological and compensatory mechanisms. Compara-
tive genomic analysis of genome-wide gene expression
data can be used to initiate human genetic studies on spe-
cific genes in that may provide entry points in etiologi-
cally important gene pathways in DN.
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